Our data showed that the colon cancer-specific survival rate was 64.6% among patients with high SIRT3 expressions and 88.6% among patients with low SIRT3 expressions (log-rank P = 0.016) (Figure 2(a)). This evidence concerns the gene SIRT3 and malignant colon neoplasm.